Juventas Cell Therapy
Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023).
Overview
Juventas Cell Therapy was founded in Tianjin with the Chinese Academy of Medical Sciences Institute of Hematology. Its CD19 CAR-T inaticabtagene autoleucel (CNCT19) was approved by the NMPA in November 2023 for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, and is also in trials for large B-cell lymphoma.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +4
Similar pages
not linked directly; found by shared links- InstitutionInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Shares Inaticabtagene autoleucel, Acute lymphoblastic leukaemia, CAR-T cell therapy and the tag china.
- InstitutionPeking University People's Hospital
Shares Acute lymphoblastic leukaemia, CAR-T cell therapy and the tag china.
- TrialLUMMICAR STUDY 1
Shares CAR-T cell therapy and the tag china.
- TrialRELIANCE
Shares CAR-T cell therapy and the tag china.
- CompanyIASO Biotherapeutics
Shares CAR-T cell therapy and the tag china.
- PersonXiaojun Huang
Shares Acute lymphoblastic leukaemia and the tag china.
- InstitutionRenji Hospital, Shanghai Jiao Tong University
Shares CAR-T cell therapy and the tag china.
- TrialFUMANBA-1
Shares CAR-T cell therapy and the tag china.